Newborn hearing screening: Tobramycin and vancomycin are not risk factors for hearing loss

Journal of Pediatrics

Volumn 142, Issue 1, 2003, Pages 41-46

  De Hoog, Matthijs ^a,b   Van Zanten, Bert A ^a,b   Hop, Wim C ^a,b   Overbosh, Ellen ^a,b   Weisglas Kuperus, Nynke ^a,b   Van Den Anker, John N ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; AUDIOMETRY; BRAIN STEM; BRAIN STEM RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FOLLOW UP; HEARING; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; OTOTOXICITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037242818     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2003.mpd037     Document Type: Article

References (44)

1. Hess M, Finckh-Kramer U, Bartsch M, Kewitz G, Versmold H, Gross M. Hearing screening in at-risk neonate cohort. Int J Pediatr Otorhinolaryngol 1998;46:81-9.
2. Vohr BR, Carty LM, Moore PE, Letourneau K. The Rhode Island Hearing Assessment Program: experience with statewide hearing screening (1993-1996).J Pediatr 1998;133:353-7.
3. Joint Committee on Infant Hearing. 1994 position statement. ASHA 1994;36:38-41.
4. Yoshinaga-Itano C. Benefits of early intervention for children with hearing loss. Otolaryngol Clin North Am 1999;32:1089-102.
5. van Straaten I. Automated auditory brainstem response hearing screening in NICU graduates: neonatology. Amsterdam: University of Amsterdam; 2001. p. 135.
6. Mehl AL, Thomson V. Newborn hearing screening: the great omission. Pediatrics 1998;101:E4.
7. Kileny PR. New insights on infant ABR hearing screening. Scand Audiol Suppl 1988;30:81-8.
8. Jacobson JT, Jacobson CA, Spahr RC. Automated and conventional ABR screening techniques in high-risk infants. J Am Acad Audiol 1990;1:187-95.
9. White KR, Vohr BR, Maxon AB, Behrens TR, McPherson MG, Mauk GW. Screening all newborns for hearing loss using transient evoked otoacoustic emissions. Int J Pediatr Otorhinolaryngol 1994;29:203-17.
10. Borradori C, Fawer CL, Buclin T, Calame A. Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate 1997;71:1-10.
11. Duffull SB, Begg EJ. Vancomycin toxicity: what is the evidence for dose dependency? Adverse Drug React Toxicol Rev 1994;13:103-14.
12. Reyes MP, Ostrea EM Jr, Cabinian AE, Schmitt C, Rintelmann W. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 1989;161:977-81.
13. Schaad UB, Nelson JD, McCracken GH Jr. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981;3:S282-8.
14. McCormack JP, Jewesson PJ. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 1992;14:320-39.
15. Bernard PA. Freedom from ototoxicity in aminoglycoside treated neonates: a mistaken notion. Laryngoscope 1981;91:1985-94.
16. Chayasirisobhon S, Yu L, Griggs L, Westmoreland SJ, Leu N. Recording of brainstem evoked potentials and their association with gentamicin in neonates. Pediatr Neurol 1996;14:277-80.
17. Cox C, Hack M, Metz D, Fanaroff A. Auditory brainstem evoked responses for screening very low birth weight infants (VLBW): effects of gentamycin and neonatal risk factors on maturation. Pediatr Res 1979,13:524A.
18. McCracken GH Jr. Aminoglycoside toxicity in infants and children. Am J Med 1986;80:172-8.
19. Langhendries JP, Battisti O, Bertrand JM, Francois A, Darimont J, Ibrahim S, et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-30.
20. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 1997;62:392-9.
21. Lundergan FS, Glasscock GF, Kim EH, Cohen RS. Once-daily gentamicin dosing in newborn infants. Pediatrics 1999;103:1228-34.
22. Meyer C, Witte J, Hildmann A, Hennecke KH, Schunck KU, Maul K, et al. Neonatal screening for hearing disorders in infants at risk: incidence, risk factors, and follow-up. Pediatrics 1999;104:900-4.
23. Finckh-Kramer U, Gross M, Bartsch M, Kewitz G, Versmold H, Hess M. Hearing screening of high risk newborn infants. Hno 2000;48:215-20.
24. Cone-Wesson B, Vohr BR, Sininger YS, Widen JE, Folsom RC, Gorga MP, et al. Identification of neonatal hearing impairment: infants with hearing loss. Ear Hear 2000;21:488-507.
25. Peters J. An automated infant screener using advanced evoked response technology. Hear J 1986;39:25-30.
26. Hall J, Kilney P, Ruth R, Peters Kripal J. Newborn auditory screening with ALGO-1 vs conventional auditory brainstem response: American Speech-Language-Hearing Association Meeting, New Orleans La, 1987.
27. Kilney P. New insights on infant ABR hearing screening. Scand Audiol Suppl 1988;30:81-8.
28. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
29. Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996;40:2494-9.
30. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antlmicrobial agents. Br J Clin Pharmacol 1999;47:23-30.
31. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1996;14:1029-38.
32. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809.
33. Kountakis SE, Psifidis A, Chang CJ, Stiernberg CM. Risk factors associated with hearing loss in neonates. Am J Otolaryngol 1997;18:90-3.
34. MacGowan A, Reeves D. Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Chemother 1994;34:829-37.
35. Kotze A, Bartel PR, Sommers DK. Once versus twice daily amikacin in neonates: prospective study on toxicity. J Paediatr Child Health 1999;35: 283-6.
36. Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin North Am 1993;26:821-8.
37. Burkhart KK, Metcalf S, Shurnas E, O'Meara O, Brent J, Kulig K, et al. Exchange transfusion and multidose activated charcoal following vancomycin overdose. J Toxicol Clin Toxicol 1992;30:285-94.
38. Goldie WD. The brainstem auditory evoked potential in infants and children. J Clin Neurophysiol 1992;9:394-407.
39. Fortnum H, Davis A. Hearing impairment in children after bacterial meningitis: incidence and resource implications. Br J Audiol 1993;27:43-52.
40. Edwards CG, Durieux-Smith A, Picton TW. Auditory brainstem response audiometry in neonatal hydrocephalus. J Otolaryngol Suppl 1985;14:40-6.
41. Salamy A, Eldredge L, Tooley WH. Neonatal status and hearing loss in high-risk infants. J Pediatr 1989;114:847-52.
42. Pettigrew AG, Edwards DA, Henderson-Smart DJ. Perinatal risk factors in preterm infants with moderate-to-profound hearing deficits. Med J Aust 1988;148:174-7.
43. Stringer SP, Meyerhoff WL, Wright CG. Ototoxicity. In: Paparella MM, Gluckmann JL, Meyerhoff WL, editors. Otolaryngology. Philadelphia: WB Saunders; 1991. p. 1653-69.
44. Kawashiro N, Tsuchihashi N, Koga K, Kawano T, Itoh Y. Delayed post-neonatal intensive care unit hearing disturbance. Int J Pediatr Otorhinolaryngol 1996;34:35-43.